Digital Edition
Ophthalmology Times: December 2022
Volume: 47
Issue: 12
Ophthalmology Times: November 2022
Volume: 47
Issue: 11
Ophthalmology Times: October 2022
Volume: 47
Issue: 10
Ophthalmology Times: September 2022
Volume: 47
Issue: 9
Ophthalmology Times: August 2022
Volume: 47
Issue: 8
Ophthalmology Times: July 2022
Volume: 47
Issue: 7
Ophthalmology Times: June 2022
Volume: 47
Issue: 6
Ophthalmology Times: May 2022
Volume: 47
Issue: 5
Ophthalmology Times: April 2022
Volume: 47
Issue: 4
Ophthalmology Times: March 2022
Volume: 47
Issue: 3
Ophthalmology Times: February 2022
Volume: 47
Issue: 2
Ophthalmology Times: January 2022
Volume: 47
Issue: 1
Ophthalmology Times: December 2021
Volume: 46
Issue: 20
Ophthalmology Times: November 15, 2021
Volume: 46
Issue: 19
Ophthalmology Times: November 1, 2021
Volume: 46
Issue: 18
Ophthalmology Times: October 15, 2021
Volume: 46
Issue: 17
Ophthalmology Times: October 1, 2021
Volume: 46
Issue: 16
Ophthalmology Times: September 15, 2021
Volume: 46
Issue: 15
Ophthalmology Times: September 1, 2021
Volume: 46
Issue: 14
Ophthalmology Times: August 2021
Volume: 46
Issue: 12
Ophthalmology Times: July 15, 2021
Volume: 46
Issue: 12
Ophthalmology Times: July 1, 2021
Volume: 46
Issue: 11
Ophthalmology Times: June 15, 2021
Volume: 46
Issue: 10
Ophthalmology Times: June 1, 2021
Volume: 46
Issue: 09
Ophthalmology Times: May 2021
Volume: 46
Issue: 8
Ophthalmology Times: April 15, 2021
Volume: 46
Issue: 7
Ophthalmology Times: April 1, 2021
Volume: 46
Issue: 6
Ophthalmology Times: March 15, 2021
Volume: 46
Issue: 5
Ophthalmology Times: March 1, 2021
Volume: 46
Issue: 4
Ophthalmology Times: February 15, 2021
Volume: 46
Issue: 3
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
3
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
4
PainReform launches development plan for OcuRing-K, readies phase 2 trial
5
.png "Optometry Times"){kind=logo}
